AN IN VITRO COMPARISON OF AZACITIDINE AND DECITABINE ACTIVITIES IN ACUTE MYELOID LEUKEMIA

被引：0
|
作者：
Hollenbach, P. [1 ]
Nguyen, A. [1 ]
Brady, H. [1 ]
Heise, C. [1 ]
MacBeth, K. [1 ]
机构：
[1] Celgene, San Francisco, CA USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1371
引用
收藏
页码：539 / 539
页数：1
相关论文
共 50 条
  • [21] Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy
    Maurillo, L.
    Spagnoli, A.
    Candoni, A.
    Papayannidis, C.
    Borlenghi, E.
    Lazzarotto, D.
    Fianchi, L.
    Sciume, M.
    Zannier, M. E.
    Buccisano, F.
    Del Principe, M. I.
    Mancini, V.
    Breccia, M.
    Fanin, R.
    Todisco, E.
    Lunghi, M.
    Palmieri, R.
    Fracchiolla, N.
    Musto, P.
    Rossi, G.
    Venditti, A.
    LEUKEMIA RESEARCH, 2023, 127
  • [22] Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
    Bingbing Wen
    Weiwen You
    Sitian Yang
    Xin Du
    Experimental Hematology & Oncology, 9
  • [23] Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia
    Manda, Sudhir
    Anz, Bertrand
    Benton, Christopher
    Broun, E. Randolph
    Yimer, Habte
    Renshaw, John
    Geils, George F.
    Cruz, Jose
    Fanning, Suzanne
    Melear, Jason
    Sharman, Jeff P.
    Kang, Kingston
    Svensson, Anders
    Pai, Madhavi
    Donnellan, William
    BLOOD, 2021, 138
  • [24] An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
    Othman, Tamer A.
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Azenkot, Tali
    Jonas, Brian A.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 407 - 417
  • [25] DECITABINE AS THERAPY FOR A PATIENT WITH ACUTE MYELOID LEUKEMIA SECONDARY TO MYELODYSPLASTIC SYNDROME TREATED WITH AZACITIDINE: A CASE REPORT
    Guaragna, G.
    Rinaldi, E.
    Spina, A.
    Mele, G.
    Quarta, G.
    Melpignano, A.
    HAEMATOLOGICA, 2017, 102 : 159 - 159
  • [26] Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality
    Talati, Chetasi
    Kuykendall, Andrew
    Al Ali, Najla
    Kim, Jongphil
    Sehovic, Marina
    Zuckerman, Kenneth S.
    Sallman, David A.
    List, Alan F.
    Padron, Eric
    Komrokji, Rami S.
    Djulbegovic, Benjamin
    Extermann, Martine
    Sweet, Kendra
    Lancet, Jeffrey E.
    BLOOD, 2017, 130
  • [27] Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
    Briot, Thomas
    Roger, Emilie
    Lautram, Nolwenn
    Verger, Alexis
    Clavreul, Anne
    Lagarce, Frederic
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 : 8427 - 8442
  • [28] The Role of Decitabine for the Treatment of Acute Myeloid Leukemia
    Ganetsky, Alex
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (11) : 1511 - 1517
  • [29] A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia
    Li-xia Zhu
    Rong-rong Chen
    Lu-lu Wang
    Jia-nai Sun
    De Zhou
    Li Li
    Jie-jing qian
    Yi Zhang
    Hong-yan Tong
    Wen-juan Yu
    Hai-tao Meng
    Wen-yuan Mai
    Wan-zhuo Xie
    Jie Jin
    Xiu-jin Ye
    Hong-hu Zhu
    Supportive Care in Cancer, 2022, 30 : 7031 - 7038
  • [30] The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine
    Doyel, Michael
    Bouligny, Ian Michael
    Murray, Graeme
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Thuy Ho
    Zacholski, Kyle
    Venn, Chad Michael
    Alnimer, Yanal Mufeed
    Wages, Nolan
    Grant, Steven
    Maher, Keri Renee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345